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Background: Cambodia stopped using co-blistered, non-fixed, artesunate-mefloquine (ASMQ) in 2008 when
treatment failure rates approximated 20%. Fixed dose combination (FDC) ASMQ is efficacious against acute
uncomplicated, drug resistant Plasmodium falciparum malaria in Southeast Asia but has not been tested in Cambodia.
Methods: A 42-day WHO therapeutic efficacy study (TES) was conducted in 2010 in Oral, Kampong Speu province, south-
west Cambodia, in patients with acute uncomplicated P. falciparum. Daily administered FDC ASMQ for three days was
dosed by age. Genotyping of isolates at day 0 and day of recrudescence by polymerase chain reaction (PCR) classified post-
treatment recurrent falciparum parasitaemia. Ex vivo drug sensitivity testing ([3H] hypoxanthine method) was performed on
baseline parasites and reported as the drug concentration inhibiting 50% parasite growth vs no drug (IC50).
Results: Recruited patients numbered 45; five aged <15 years. On day 3, five of 45 [11.1 (3.7-24.05)] % patients were still
parasite-positive; one of whom later failed treatment on day 21. There were 5/45 (11.1%) late treatment failures on day 21,
28 and 35; all were PCR diagnosed recrudescent infections. The day 0 MQ IC50s ranged from 11.5-238.9 (median 58.6) nM.
Conclusions: This TES demonstrated reasonable efficacy in an area of possible reduced artemisinin sensitivity and high MQ
IC50s. Efficacy testing of FDC ASMQ should continue in Cambodia and be considered for reintroduction if efficacy returns.
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The first artemisinin-based combination therapy (ACT) to
be introduced in 2000 by the National Malaria Control
Programme in Cambodia (CNM, Centre National de
Malariologie) to treat drug-resistant Plasmodium falcip-
arum was non-fixed artesunate-mefloquine (NF-ASMQ).
Prior to this, there had been a long history of anti-malarial
drug resistance, starting with chloroquine [1] in the early
1960s, followed by sulphadoxine-pyrimethamine (SP) [2],
mefloquine (MQ) [3] and SP combined with MQ [4].
NF-ASMQ was co-blistered (i e, both drugs in the same
blister). There were five age-weight dosing categories and* Correspondence: rithealeang@gmail.com
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reproduction in any medium, provided the orthe maximum MQ dose was capped at 1,500 mg because
of its poor tolerability [5]. When dosed by age rather than
weight, a substantial minority of patients (~30% of all pa-
tients, ~43% adults) received less than the total target
doses of AS and MQ over 48 hours, i e, <12 mg/kg of AS
and <20 mg/kg of MQ. Nevertheless, between 2001 to
2004, therapeutic efficacy studies (TESs), conducted
across Cambodia, demonstrated generally PCR-corrected
rates of adequate clinical and parasitological response
(ACPR) exceeding 90% when assessed over 28 days [5,6].
However, as early as 2001, the day 28 ACPR rate in Pailin
was low at 85.7% and was about the same, 90.1%, in 2004.
A subsequent, day 42 follow-up TES in 2004 in Pailin
demonstrated an ACPR of just under 80% [5]. Analyses of
some of the falciparum parasites from these TESs [6]
showed a significantly lower geometric mean MQ IC50td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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50% compared to a no-drug control) in parasites with 1
Pfmdr-1 copy number compared with parasites with ≥2
copies (27.9 nM vs 50.3 nM) and a lower median Pfmdr-1
copy number in patients with ACPR compared those who
failed treatment: 1.5 vs 2.4 [7]. The risk of failing ASMQ
was about eight-fold more likely with ≥3 Pfmdr-1 copy
numbers [7].
NF-ASMQ TESs conducted in 2007 in Veal Veng
(Pursat province, western Cambodia) and in 2006–08 in
Chumkiri (Kampot province, south-western Cambodia)
demonstrated day 42 PCR-corrected failure rates of 16%
and just under 19%, respectively [8,9]. Independent risk
factors for treatment failure in Kampot were a high day
0 parasite density, longer time to clear parasites and an
increasing Pfmdr-1 copy number [9].
In vitro drug sensitivity data from Chumkiri showed
that the MQ IC50s ranged from approximately 15 to 180
nM ([3H] hypoxanthine method) and a higher mean
IC50 was reported in resistant infections (90 nM) vs sen-
sitive (56 nM) infections [9]. These high IC50 values are
consistent with in vitro data from Lim et al. who
reported a geometric mean IC50 of 50.57 nM in MQ fail-
ures vs 23.85 nM in ACPR patients from west and east
Cambodia combined in studies from 2001 to 2007 [10].
Based on these high failure rates and the earlier poor effi-
cacy of artemether-lumefantrine [6], ASMQ was replaced by
fixed dose dihydroartemisinin-piperaquine (DHA-PP) in
2008 because of its convenient daily dosing and high efficacy
in Cambodia [11] and elsewhere in southeast Asia [12].
Recent DHA-PP efficacy data from western Cambodia,
on relatively small patient numbers, have been discour-
aging. PCR-corrected failure rates of 25 and 10% have
been reported from Pailin and Pursat, respectively; both
areas have high rates (19 and 27%, respectively) of pfmdr1
positive falciparum parasites and in vitro data character-
ized by high IC50s for MQ [13]. Western Cambodia has
well documented artemisinin resistance (AR), manifest as
slow asexual parasite clearance and a consequential in-
crease in gametocytogenesis [14]; thus, ACT failures may
be due to AR, partner drug resistance and poor drug ab-
sorption or a combination of all three.
FDC-ASMQ, a comparatively new ACT, has been
WHO prequalified [15] but has never been tested in
Cambodia. If its efficacy were high enough, it could be
recommended by CNM. Herein, the results of a TES
using the fixed dose ASMQ in Cambodia are reported.
Methods
Study design and site
This standard WHO TES [16] was conducted in Oral
Health Centre in Oral district, Kampong Speu province,
about 100 km south-west of Phnom Penh (Figure 1).
Malaria is seasonal with an approximate Plasmodiumfalciparum: Plasmodium vivax ratio of 2:1. The high
transmission season is from June to November [17].
The study took place from September 2010 to January
2011. In vitro data (P Lim, unpublished observations
but aggregated in reference [10]) from this area in 2001
(n = 13 isolates) and 2003 (n = 54) show median (inter-
quartile ranges, [full ranges]) IC50s for MQ of 17.3 nM
(14.6-36.1) [11.9-69.9] and 8.4 nM (3.6-27.5) [1–143.4],
respectively.
The study was approved by the National Ethic Committee
for Health Research of the Ministry of Health, Cambodia.
Patients
Patients who attended the Oral Health Centre were en-
rolled if they met all of the following inclusion criteria:
(i) informed consent was signed; (ii) they had a docu-
mented fever or a history of fever within the previous 48
hours; (iii) microscopic P. falciparum between 1,000 and
200,000 asexual parasites/μL; and, (iv) were aged two
years and above.
Exclusion criteria included: (i) pregnant or breast feeding
women; (ii) unable to complete the follow-up; (iii) allergic
to AS or MQ; (iv) a neuropsychiatric contraindication to
MQ, namely, epilepsy, history of a severe psychiatric illness,
e g, bipolar affective disorder, psychosis, anxiety neurosis;
(v) presence of any danger signs or any sign of signs of se-
vere malaria [18]; (vi) severe malnutrition; and, (vii) known
severe underlying disease.
Study conduct
Patients who were malaria slide-positive were asked if they
were interested to join a research study. After informed
consent was signed, they were assessed to see if they met
the criteria for study enrolment. This involved a medical
history, physical and blood examinations for a repeat mal-
aria slide (Giemsa-stained and read in the field), haemato-
crit, total white cell count and blood glucose.
Parasite counts were determined on Giemsa-stained thick
films and recorded as the number of parasites per 200 white
blood cells. Two qualified microscopists read independently
all malaria slides and parasite densities were recorded as the
average of these two counts. Slides were to be reread if the
parasitaemia difference was >50%. The parasitaemia/μL was
determined by multiplying the parasite count/200 white cells
by 40. A slide was declared negative after reading 100 thick
film fields.
Filter-paper blood spots were collected on day 0 and on
the day of recurrent parasitaemia to determine if the re-
currence was a resistant (recrudescent) or new infection
by the polymerase chain reaction (PCR) amplification of
the genes of the merozoite surface protein 1 and 2 (msp 1,
msp 2) and the glutamate rich protein (glurp) [19].
Patients were followed up for 42 days. They were seen
daily for temperature measurement, asked about symptoms
Figure 1 Location of the study sites, Oral, Kampong Speu province, Cambodia.
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slides were negative. Thereafter, they were seen weekly
from days 7 to 42. Home visits were done if patients missed
their appointments.
Study drug
ASMQ, supplied by Farmanguinhos in Brazil, was ad-
ministered under supervision in the clinic, following the
manufacturer’s instructions. Each higher dose tablet
contained 100 mg artesunate and 220 mg mefloquine
hydrochloride (200 mg base) and each lower dose tablet
25 and 55 mg, respectively. The doses were: (i) adults
(≥13 years) - two high-dose tablets per day for three
days; (ii) older children, seven to 12 years, one high-dose
tablet per day for three days; and, (iii) younger children
one to six years, two lower-dose tablets per day for three
days.
If vomiting occurred within 30 minutes, a full dose
(two tablets) was to be re-administered; if between 31
and 60 minutes, one tablet. All treatments were given
supervised by study nurses. Other drugs were allowed to
be given as clinically indicated, e. g, paracetamol for
fever and an antiemetic for nausea and vomiting. Drugs
with anti-malarial activity, e g, certain antibiotics were
not given unless necessary.
Outcomes
Efficacy outcomes were based on the WHO TES classifi-
cations: adequate clinical and parasitological response
(ACPR), late parasitological failure (LPF), late clinical
failure (LCF) and early treatment failure (ETF) [20].Primary endpoint
The primary endpoint was day 42, PCR-corrected, Kaplan
Meier (KM) proportions of patients with an ACPR.
Secondary endpoints
The secondary efficacy endpoints were: (i) the propor-
tions of patients with positive parasites on day 3; (ii)
parasite clearance time (PCT): the time in days for two
successive malaria slides to become and remain negative;
(iii) fever clearance time (FCT): time to become afebrile
for at least 24 hours; and, (iv) gametocyte carriage (pro-
portion of patients gametocyte positive) over time.
Definitions of treatment failure
An ETF was defined as: (i) the development of severe mal-
aria within the first 72 hours; (ii) a day 2 parasite count >
day 0 parasite count; (iii) a day 3: day 0 parasite count ≥25%;
and, (iv) parasitaemia on day 3 with fever. A LTF was an ini-
tial clearing of parasites by day 7 followed by a recurrence of
falciparum parasitaemias without fever. A LCF was a LTF
with a fever.
In accordance with WHO recommendations, treatment
failure was labelled recrudescence if all msp-1, msp-2, and
glurp alleles present at the time of failure had been present
at the time of treatment initiation [21]. In all other cases,
the failure was considered a new infection.
Treatment emergent symptoms and signs
A treatment emergent symptom and sign (TESS) was
defined as being absent pre-FDC-ASMQ but reported or
detected post-drug administration. TESSs were sought





Age years† 22 (7–56)
Age 2–15 years* 5 (11.11)
Adults* 40 (88.89)
Weight in kg† 50 (18–67)
Temperature in °C† 38.5 (36.8-40.8)
Febrile (≥37.5°C)* 39 (86.67)
Parasitaemia in N/μl† 15,778 (10,215-24,369)
Gametocyte positive* 0 (0)
Haematocrit % † 38 (34–43)
Artesunate dose in mg/kg in 48 h 12 (10.9-13.9, 8.9-17.1)
Mefloquine dose in mg/kg in 48 h 24 (21.8-27.9, 17.9-34.3)
* N (%); † Median (range); Median (interquartile range, range).
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severity. A serious adverse event (AE) was an AE with
at least one of the following characteristics: (i) life-
threatening; (ii) resulted in death; (iii) caused residual
significant disability; or, (iv) resulted in a prolongation
of a patient’s hospital stay [22].
Ex vivo drug sensitivity testing
Ex vivo drug sensitivity testing was performed at the
Institut Pasteur du Cambodge (IPC) using the 48 hours
[3H] hypoxanthine isotopic method [23], the same
method used in earlier studies [10]. Samples were only
tested if they arrived within 48 hours of being taken, the
patient had not taken anti-malarial drugs and the para-
sitaemia was between ~0.1 to 1%.
Briefly, artesunate, chloroquine, dihydroartemisinin, mef-
loquine, and quinine were obtained from Sigma-Aldrich
(Singapore) and piperaquine from Yick-Vic Chemicals &
Pharmaceuticals (Hong Kong). Stock solutions of anti-
malarial drugs were prepared in 0.5% lactic acid for
piperaquine, and methanol for the other drugs. The final
plate concentrations ranged from 0.1-102.4 nM for
artesunate, 5–5,120 nM for chloroquine, 0.0625-64 nM for
dihydroartemisinin, 1–1,024 nM for mefloquine, 2–2,000
nM for piperaquine, and 6.25- 6,400 nM for quinine. Each
concentration was used to coat two wells in a 96-well flat-
bottom plate (ATGC, France). Forty μl of drug solutions
were added to each well. Plates were dried into a laminar
flow hood (per batch of 30 plates) and kept at 4°C until they
were used. Batches of pre-dosed plates were prepared
weekly and generally used within two weeks after prepar-
ation. Their suitability for in vitro testing was monitored
regularly using the reference P. falciparum strain 3D7
maintained in continuous culture. The results of the
in vitro assay were expressed as the 50% inhibitory concen-
tration (IC50), defined as the concentration at which 50% of
the incorporation of [3H] hypoxanthine was inhibited, com-
pared to the drug-free control wells. These IC50s are deter-
mined by non-linear regression using the ICEstimator [24].
Data management and statistical analysis
The sample size was calculated based on standard WHO
criteria and used the precision method [20]. With a confi-
dence of 95%, an assumed failure rate of 15% with 10% pre-
cision (i e, from 5 to 25%), the estimated sample size was
50 evaluable patients. In accordance with WHO TES,
Kaplan Meier (KM) analysis was used to assess the day 42
cure rate [20]. Data were collected onto a standard case
record form (CRF) and double entered in the WHO Excel
spreadsheet. Stata version 10.1 (Stata Corp, College Station,
TX, USA) was used for statistical analysis. Patients were in-
cluded in the KM analysis if they received at least one dose
of FDC-ASMQ. Patients without a parasitological endpoint,
e g, lost to follow-up, were censored in the KM analysis.Continuous data were summarized using mean, standard
deviation (SD), median, interquartile (IQR) and full ranges
and compared by t-test (normally distributed data) or the
Mann Whitney U tests (skewed data). Simple proportions
were compared using chi squared. P-values of ≤0.05 were
considered statistically significant.Role of the funding agency
The Drugs for Neglected Diseases initiative (DNDi) funded
the study, monitored the fieldwork and contributed to this
publication.Results
Fifty patients were screened, five did not meet the entry
criteria and 45 were enrolled. The majority of patients
were adults of median age 22 years; 38 patients were males
(Table 1). Patient flow in the study was characterized by
no losses to follow-up and five patients with recurrent
parasitaemia.
The median total daily doses over 48 hours of AS and
MQ were 12 and 24 mg/kg, respectively (Table 1). Two pa-
tients aged <13 years were inadvertently given two FDC
tablets per day instead of one. Excluding these two, the me-
dian doses received were 11.8 and 23.5 mg/kg, respectively.
Had the patients received NF ASMQ, as recommended by
the May 2012 National Treatment Guidelines, median
(range) doses would have been 11.8 (8.3-15) mg/kg for AS
and 22 (12.5-28.1) mg/kg. The mean difference in the MQ
dose between the FDC and NF ASMQ (excluding the two
given the wrong dose) was 1.9 mg/kg (p < 0.0001).
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Primary efficacy endpoint
There were no cases of ETF. By day 42, there were five
LCFs which occurred on days 21 (n = 1), 28 (n = 3) and 35
(n = 1). All were classed as recrudescences for a KM cure
rate of 88.9 (75.3-95.2) %. The median total doses of AS
and MQ in the recrudescent infections were essentially
the same as the cured patients: 12 vs 11.9 and 23.7 vs 24
mg/kg, respectively.
Day 3 positivity
On day 3 (72 hours), five of 45 [11.1 (3.7-24.05)] % patients
were still parasite-positive; one of whom later failed treat-
ment on day 21. Their day 0 day 3 parasite counts (N/μL)
were: 13,067-270, 14,074-953, 30,718-1872, 46083–434, and
108,013-134.
Parasite and fever clearance times
The PCT ranged from two to seven days for a median of
three days. All febrile patients at presentation (n = 39)
were afebrile by day 2 for a median FCT of 24 hours.
Gametocyte carriage
Gametocytes were not detected on days 0 to 21 and 35
and 42; 4/44 (9.1%) patients had gametocytes on day 28.
TESS
ASMQ was well tolerated acutely. There were no patients
with drug-induced vomiting who needed rescue treat-
ment. Over the first three days, seven patients reported
adverse events, five of whom had received >24 mg/kg of
mefloquine. Two (4.4%) patients complained of dizziness,
five (11.1%) complained of nausea, and five (11.1%)
complained of palpitations. Of these, one complained of
all three symptoms and three complained of nausea and
palpitations. None required treatment.
Ex vivo drug sensitivity testing
Among the 45 isolates collected, 18 met the criteria for
ex vivo testing. These 18 patients had similar baseline
characteristics and received similar drug doses as the








Quinine 13 365.8untested patients with parasite counts≤ 5,000/μL, the me-
dian baseline parasite counts were not significantly different
similar (p = 0.37): 39,815 (n = 18) vs. 20,103/μL (n = 19).
The median IC50s (including IQR and range) are presented
in Table 2. The variation in IC50 values varied from four-
fold (piperaquine) to approximately 60-fold (CQ). Of the 16
ASMQ treated patients with IC50 data, only one was
classed as a treatment failure: 55.3 nM. The IC50 values in
patients with ACPR ranged 11.5 to 238.92 for a median of
58.74 nM. The results were almost the same when stratify-
ing by day 3 positivity.
Using WHO suggested [25] in vitro IC50 cut off values
for distinguishing resistant from sensitive parasites (30
nM for mefloquine, 400 nM quinine, and 100 nM for
CQ): (i) 14/16 MQ tested parasites had evidence of
in vitro resistance: median (range) IC50 = 65 nM (35–
239); (ii) 5/13 (quinine) IC50 = 666 nM (603–725); and,
(iii) 13/16 (CQ) IC50 = 209 nM (138–302).Discussion
This TES has shown that the FDC-ASMQ was reason-
ably effective in an area of south-west Cambodia, achiev-
ing a day 42 cure rate a little under 90%, in the face of
in vitro data suggesting reduced MQ sensitivity and
where the day 3 positivity rate exceeded the original 3%
cut-off [26] for suggesting reduced artemisinin sensitivity
as well as the 10% cut-off adapted by WHO for malaria
control programmes [25].
NF-ASMQ was used on a national scale from 2000
until 2008 when it was replaced by DHA-PP after failure
rates of some ~20% were reported from Pailin and
Kampot [8]. Thus, this FDC-ASMQ TES study was done
after an interval of approximately two years since NF-
ASMQ was replaced in Cambodia.
The FDC-ASMQ doses administered to the patients
were almost identical for AS but the mean MQ dose was
slightly higher compared to the Cambodian, NF-ASMQ
dosing recommendations. Although about half of the pa-
tients received doses under the targeted doses of AS and
MQ, none received <6 mg/kg of AS, the suggested thera-
peutic minimum [27], and none received <15 mg/kg of
MQ, a minimum suggested by malariologists. The failurey tests
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dence interval is wide, ranging from <5 to <25%. Therefore,
caution is warranted in interpreting this result even though
it appears better than failure rates reported earlier from
Pailin and Kampot.
The MQ in vitro data in this study were characterized
by a high median IC50, ~three- to seven-fold higher
compared to data obtained in 2001 and 2003 in Oral, re-
spectively, and is comparable to geometric mean in vitro
values associated with NF-ASMQ treatment failures in
some studies [10] but is lower than the median IC50
found by Rogers et al. in Kampot in resistant infections
(90 nM) [9]. As expected, the relatively high day 3 posi-
tivity rate and the in vitro data appear to have had little
predictive value for ASMQ failure.
Malaria control programmes should be aware that
the day 3 positivity rate is an indicator of the possibility
that parasites may be artemisinin resistant [28] and that
this should trigger a more detailed in vivo investigation
in which the parasite clearance half-life should be mea-
sured. The current in vitro methods are useful to track
trends over time but are insensitive for detecting
artemisinin resistance. However, a new in vitro test,
the RSA (Ring-stage Survival Assay) [29], is showing
promise in correlating with slow parasite clearance in
patients [30].
The study had limitations. The number of patients en-
rolled in the TES was quite small, 45, due to the low mal-
aria burden and this reduces the strength of the study
conclusions. Most patients recruited were adult males,
consistent with the malaria epidemiology in other areas of
Cambodia. Follow-up extended to day 42 so the true fail-
ure rate may have been a little higher had follow-up ex-
tended to 63 days, the recommended follow-up time for
long half drugs such as mefloquine [31]. These limit the
ability to interpret and apply the results. The Pfmdr-1
copy number was not counted. This molecular marker of
reduced MQ sensitivity [32] is another good marker of the
trends in MQ sensitivity. Indeed, in Pailin, the Pfmdr-1
copy number declined markedly from 33% in 2005 to 5%
in 2007 [33]. The WHO TES places little emphasis on the
collection of tolerability data. Thus, the tolerability data
reported here focused only on new, post-treatment TESS.
This was a limitation but the toxicity of MQ and NF-
ASMQ is well characterized.
To conclude, this TES has benchmarked in the in vivo
and in vitro status of FDC-ASMQ in Oral. The 11% fail-
ure rate is not discouraging and CNM should continue
to monitor FDC-ASMQ efficacy, preferably to day 63, in
conjunction with in vitro data and Pfmdr-1 copy number
to see if FDC-ASMQ can be recommended in the future
for treating symptomatic patients. FDC-ASMQ should
also be assessed in PCR positive asymptomatic individ-
uals for a potential role in malaria elimination.Competing interests
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